This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhu, Z.
Right arrow Articles by Dimitrov, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhu, Z.
Right arrow Articles by Dimitrov, D. S.

 Previous Article  |  Next Article 

Journal of Virology, January 2006, p. 891-899, Vol. 80, No. 2
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.2.891-899.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Potent Neutralization of Hendra and Nipah Viruses by Human Monoclonal Antibodies

Zhongyu Zhu,1,2 Antony S. Dimitrov,3 Katharine N. Bossart,3,{dagger} Gary Crameri,4 Kimberly A. Bishop,3 Vidita Choudhry,1 Bruce A. Mungall,4 Yan-Ru Feng,3 Anil Choudhary,3 Mei-Yun Zhang,1,2 Yang Feng,1 Lin-Fa Wang,4 Xiaodong Xiao,1 Bryan T. Eaton,4 Christopher C. Broder,3* and Dimiter S. Dimitrov1*

Protein Interactions Group, CCRNP, CCR, NCI-Frederick, NIH, Frederick, Maryland 21702,1 BRP, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland 21702,2 Department of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland 20814,3 CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia4

Received 28 August 2005/ Accepted 19 October 2005

Hendra virus (HeV) and Nipah virus (NiV) are closely related emerging viruses comprising the Henipavirus genus of the Paramyxovirinae. Each has a broad species tropism and can cause disease with high mortality in both animal and human hosts. These viruses infect cells by a pH-independent membrane fusion event mediated by their attachment (G) and fusion (F) envelope glycoproteins (Envs). Seven Fabs, m101 to -7, were selected for their significant binding to a soluble form of Hendra G (sG) which was used as the antigen for panning of a large naïve human antibody library. The selected Fabs inhibited, to various degrees, cell fusion mediated by the HeV or NiV Envs and virus infection. The conversion of the most potent neutralizer of infectious HeV, Fab m101, to immunoglobulin G1 (IgG1) significantly increased its cell fusion inhibitory activity: the 50% inhibitory concentration was decreased more than 10-fold to approximately 1 µg/ml. The IgG1 m101 was also exceptionally potent in neutralizing infectious HeV; complete (100%) neutralization was achieved with 12.5 µg/ml, and 98% neutralization required only 1.6 µg/ml. The inhibition of fusion and infection correlated with binding of the Fabs to full-length G as measured by immunoprecipitation and less with binding to sG as measured by enzyme-linked immunosorbent assay and Biacore. m101 and m102 competed with the ephrin-B2, which we recently identified as a functional receptor for both HeV and NiV, indicating a possible mechanism of neutralization by these antibodies. The m101, m102, and m103 antibodies competed with each other, suggesting that they bind to overlapping epitopes which are distinct from the epitopes of m106 and m107. In an initial attempt to localize the epitopes of m101 and m102, we measured their binding to a panel of 11 G alanine-scanning mutants and identified two mutants, P185A and Q191 K192A, which significantly decreased binding to m101 and one, G183, which decreased binding of m102 to G. These results suggest that m101 to -7 are specific for HeV or NiV or both and exhibit various neutralizing activities; they are the first human monoclonal antibodies identified against these viruses and could be used for treatment, prophylaxis, and diagnosis and as research reagents and could aid in the development of vaccines.

* Corresponding author. Mailing address for D. S. Dimitrov: CCRNP, CCR, NCI-Frederick, NIH, Bldg. 469, Rm. 105, Frederick, MD 21702-1201. Phone: (301) 846-1352. Fax: (301) 846-5598. E-mail: dimitrov{at}ncifcrf.gov. Mailing address for C. C. Broder: Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814. Phone: (301) 295-3401. Fax: (301) 295-1545. E-mail: cbroder{at}usuhs.mil.

{dagger} Present address: CSIRO Livestock Industries, Australian Animal Health Laboratory, Geelong, Victoria 3220, Australia.

Journal of Virology, January 2006, p. 891-899, Vol. 80, No. 2
0022-538X/06/$08.00+0     doi:10.1128/JVI.80.2.891-899.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Klein, J. S., Gnanapragasam, P. N. P., Galimidi, R. P., Foglesong, C. P., West, A. P. Jr, Bjorkman, P. J. (2009). Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl. Acad. Sci. USA 106: 7385-7390 [Abstract] [Full Text]  
  • Bowden, T. A., Crispin, M., Harvey, D. J., Aricescu, A. R., Grimes, J. M., Jones, E. Y., Stuart, D. I. (2008). Crystal Structure and Carbohydrate Analysis of Nipah Virus Attachment Glycoprotein: a Template for Antiviral and Vaccine Design. J. Virol. 82: 11628-11636 [Abstract] [Full Text]  
  • Bishop, K. A., Hickey, A. C., Khetawat, D., Patch, J. R., Bossart, K. N., Zhu, Z., Wang, L.-F., Dimitrov, D. S., Broder, C. C. (2008). Residues in the Stalk Domain of the Hendra Virus G Glycoprotein Modulate Conformational Changes Associated with Receptor Binding. J. Virol. 82: 11398-11409 [Abstract] [Full Text]  
  • Chen, W., Zhu, Z., Feng, Y., Dimitrov, D. S. (2008). Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc. Natl. Acad. Sci. USA 105: 17121-17126 [Abstract] [Full Text]  
  • Zhu, Z., Chakraborti, S., He, Y., Roberts, A., Sheahan, T., Xiao, X., Hensley, L. E., Prabakaran, P., Rockx, B., Sidorov, I. A., Corti, D., Vogel, L., Feng, Y., Kim, J.-O., Wang, L.-F., Baric, R., Lanzavecchia, A., Curtis, K. M., Nabel, G. J., Subbarao, K., Jiang, S., Dimitrov, D. S. (2007). Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc. Natl. Acad. Sci. USA 104: 12123-12128 [Abstract] [Full Text]  
  • Bishop, K. A., Stantchev, T. S., Hickey, A. C., Khetawat, D., Bossart, K. N., Krasnoperov, V., Gill, P., Feng, Y. R., Wang, L., Eaton, B. T., Wang, L.-F., Broder, C. C. (2007). Identification of Hendra Virus G Glycoprotein Residues That Are Critical for Receptor Binding. J. Virol. 81: 5893-5901 [Abstract] [Full Text]  
  • Mungall, B. A., Middleton, D., Crameri, G., Bingham, J., Halpin, K., Russell, G., Green, D., McEachern, J., Pritchard, L. I., Eaton, B. T., Wang, L.-F., Bossart, K. N., Broder, C. C. (2006). Feline Model of Acute Nipah Virus Infection and Protection with a Soluble Glycoprotein-Based Subunit Vaccine. J. Virol. 80: 12293-12302 [Abstract] [Full Text]  
  • Guillaume, V., Aslan, H., Ainouze, M., Guerbois, M., Fabian Wild, T., Buckland, R., Langedijk, J. P. M. (2006). Evidence of a Potential Receptor-Binding Site on the Nipah Virus G Protein (NiV-G): Identification of Globular Head Residues with a Role in Fusion Promotion and Their Localization on an NiV-G Structural Model.. J. Virol. 80: 7546-7554 [Abstract] [Full Text]  
  • Prabakaran, P., Gan, J., Feng, Y., Zhu, Z., Choudhry, V., Xiao, X., Ji, X., Dimitrov, D. S. (2006). Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody. J. Biol. Chem. 281: 15829-15836 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»